Skip to main content
$11.47 $0.43 (3.9%)

04:00 PM EDT on 07/01/22

Iovance Biotherapeutics Inc (NASDAQ:IOVA)

CAPS Rating: 2 out of 5

Current Price $11.47 Mkt Cap $1.8B
Open $11.06 P/E Ratio 0.00
Prev. Close $11.47 Div. (Yield) $0.00 (0.0%)
Daily Range $10.94 - $11.62 Volume 4,141,693
52-Wk Range $6.18 - $27.96 Avg. Daily Vol. 6,534,112

Caps

How do you think NASDAQ:IOVA will perform against the market?

Add Stock to CAPS Watchlist

All Players

35 Outperform
22 Underperform
 

All-Star Players

9 Outperform
13 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:IOVA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

zzlangerhans (99.77)
Submitted June 08, 2016

#zzporte has owned Lion since 2014 but I never could get excited enough about the position to enter a green thumb. The stock has gyrated quite a bit since we took our initial position but we never took advantage of the cycles and I recently… More

NASDAQ:IOVA Summary

Recent Community Commentary

Read the most recent pitches from players about IOVA.

Recs

0
Member Avatar kkconway (99.46) Submitted: 6/15/2022 2:54:31 PM : Outperform Start Price: $8.05 NASDAQ:IOVA Score: +40.84

INSIDERS BUYING since the stock price was halved by skittish investors who were spooked by latest phase 3 trial results; insiders are more confident the results were plenty good enough for the FDA to approve this novel cancer treatment.

Recs

0
Member Avatar LohShiSan (97.11) Submitted: 5/9/2020 3:03:38 AM : Outperform Start Price: $33.58 NASDAQ:IOVA Score: -101.93

With the goal of stomping out cancer, Iovance develops transformative immuno-oncology tumor-infiltrating lymphocytes (TIL) therapies that use the power of a patient’s own immune system.After its collaborator, Moffitt Cancer Center, provided an update on the Phase 1 testing of TILs plus nivolumab in CKI-naïve metastatic non-small-cell lung carcinoma (NSCLC) patients, the stock is on Wall Street’s radar. In order to be eligible, patients needed to be anti-PD-1 naïve and at least one safely accessible metastasis from where TILs were isolated had to be present.Looking at the data, the therapy was effective in 25% of patients, with two complete responses recorded. On top of this, the key analysis indicates that in order to spur a clinical response, TILs need to survive and circulate systematically.Further explaining this, H.C. Wainwright’s Joseph Pantginis noted, “Importantly, the authors also demonstrated that neoantigen positive T cells represented 21% of total TIL clonotypes. Although TIL clonotype persistence declines with time in the blood of these patients, persistent and stable levels of infused T cells associated with higher tumor killing and response. Thus, we believe that methods to enrich for these TIL populations, such as Iovance’s next generation TILs could be critical to drive better clinical responses.” As NSCLC is a notoriously difficult indication to address, Pantginis argues that the results should be interpreted as a major positive. With this in mind, he left a “buy” rating on IOVA. Along with his bullish call, the analyst lifted the price target from $36 to $48. This brings the upside potential to 50%. With 100% Street support, or nine “buy” ratings set in recent months, the consensus is unanimous: IOVA is a “strong buy.”

Recs

0
Member Avatar techjunkie89 (23.53) Submitted: 5/3/2020 11:27:15 PM : Outperform Start Price: $31.68 NASDAQ:IOVA Score: -99.84

Leading cell therapy player with efficacy shown in solid tumors, strong buyout potential

Leaderboard

Find the members with the highest scoring picks in IOVA.

Score Leader

SueInVirginia

SueInVirginia (85.17) Score: +465.74

The Score Leader is the player with the highest score across all their picks in IOVA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
DorminABC 99.85 7/25/2011 Underperform NS $154.00 -92.59% +186.06% +278.66 0 Comment
Zencyclone 29.16 3/17/2015 Underperform 5Y $13.32 -14.38% +83.60% +97.98 0 Comment
monkeyjaws 40.16 3/12/2015 Underperform 5Y $12.39 -7.95% +84.20% +92.15 0 Comment
Mangot1me 47.14 3/24/2015 Underperform 5Y $12.23 -6.75% +81.71% +88.46 0 Comment
GreenAB 29.90 3/12/2015 Underperform NS $11.40 +0.04% +85.77% +85.73 0 Comment
OttoLutz 84.31 7/19/2019 Underperform 5Y $26.12 -56.34% +27.45% +83.78 0 Comment
ClientNein 100.00 6/19/2019 Underperform 5Y $22.57 -49.47% +30.34% +79.81 0 Comment
Bigcaps19 91.58 9/11/2019 Underperform 5Y $20.52 -44.42% +27.55% +71.97 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. SPLNextGen1976 41.54 6/7/2022 Outperform 5Y $7.41 +54.02% -6.77% +60.79 0 Comment
roolbreakers 88.34 8/15/2016 Underperform 5Y $9.11 +25.19% +74.21% +49.01 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for IOVA.